Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Inventory (2016 - 2026)

Ani Pharmaceuticals' Inventory history spans 14 years, with the latest figure at $143.1 million for Q4 2025.

  • On a quarterly basis, Inventory rose 4.59% to $143.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $143.1 million, a 4.59% increase, with the full-year FY2025 number at $143.1 million, up 4.59% from a year prior.
  • Inventory hit $143.1 million in Q4 2025 for Ani Pharmaceuticals, down from $146.5 million in the prior quarter.
  • Over the last five years, Inventory for ANIP hit a ceiling of $148.0 million in Q3 2024 and a floor of $59.9 million in Q1 2021.
  • Historically, Inventory has averaged $110.0 million across 5 years, with a median of $106.0 million in 2022.
  • Biggest five-year swings in Inventory: soared 57.44% in 2022 and later fell 1.06% in 2025.
  • Tracing ANIP's Inventory over 5 years: stood at $89.4 million in 2021, then increased by 17.79% to $105.4 million in 2022, then increased by 5.54% to $111.2 million in 2023, then rose by 23.01% to $136.8 million in 2024, then grew by 4.59% to $143.1 million in 2025.
  • Business Quant data shows Inventory for ANIP at $143.1 million in Q4 2025, $146.5 million in Q3 2025, and $138.3 million in Q2 2025.